Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study

Table 1 Baseline characteristics

	Rebamipide/nizatidine (n = 130)	Nizatidine (n = 130)	Total (n = 260)	P value
Age (year), mean ± SD	45.96 ± 14.25	44.0 ± 13.54	44.98 ± 13.91	0.296
Sex, male, n (%)	41 (31.54)	50 (38.46)	91 (35.00)	0.242
Height (cm), mean ± SD	163.13 ± 8.19	164.95 ± 7.24	164.04 ± 7.77	0.034
Weight (cm), mean ± SD	63.25 ± 13.65	63.48 ± 12.17	63.36 ± 12.91	0.530
Body mass index (kg/m2), mean ± SD	23.61 ± 3.76	23.21 ± 3.43	23.41 ± 3.60	0.528
Smoking status, n (%)				0.688
No	107 (82.31)	104 (80.00)	211 (81.15)
Past smoker	13 (10.00)	12 (9.23)	25 (9.62)
Current smoker	10 (7.69)	14 (10.77)	24 (9.23)
Alcohol consumption, yes, n (%)				0.494
No	53 (40.77)	44 (33.85)	97 (37.31)
Past	11 (8.46)	11 (8.46)	22 (8.46)
Current	66 (50.77)	75 (57.69)	141 (54.23)
Concurrent disease, yes, n (%)	25 (19.23)	20 (15.38)	45 (17.31)	0.412
Concomitant medication, yes, n (%)	10 (7.69)	15 (11.54)	25 (9.62)	0.293
Gastrointestinal symptom scores, mean ± SD
Total	14.6 ± 10.0	15.0 ± 11.2	14.8 ± 10.6	0.758
Severity	8.5 ± 5.9	8.5 ± 6.5	8.5 ± 6.2	0.968
Frequency	6.1 ± 4.6	6.5 ± 5.0	6.3 ± 4.8	0.524